Show simple item record

dc.contributor.authorOlgac, Ufuk
dc.contributor.authorPoulikakos, Dimos
dc.contributor.authorKurtcuoglu, Vartan
dc.contributor.authorRikhtegar Nezami, Farhad
dc.contributor.authorEdelman, Elazer R
dc.date.accessioned2017-12-18T14:23:43Z
dc.date.available2017-12-18T14:23:43Z
dc.date.issued2016-07
dc.date.submitted2016-07
dc.identifier.issn0168-3659
dc.identifier.urihttp://hdl.handle.net/1721.1/112773
dc.description.abstractDrug-eluting stents are accepted as mainstream endovascular therapy, yet concerns for their safety may be under-appreciated. While failure from restenosis has dropped to below 5%, the risk of stent thrombosis and associated mortality remain relatively high. Further optimization of drug release is required to minimize thrombosis risk while maintaining therapeutic dose. The complex three-dimensional geometry of deployed stents together with the combination of diffusive and advective drug transport render an intuitive understanding of the situation exceedingly difficult. In situations such as this, computational modeling has proven essential, helping define the limits of efficacy, determine the mode and mechanism of drug release, and identify alternatives to avoid toxicity. A particularly challenging conformation is encountered in coronary arteries with overlapping stents. To study hemodynamics and drug deposition in such vessels we combined high-resolution, multi-scale ex vivo computed tomography with a flow and mass transfer computational model. This approach ensures high geometric fidelity and precise, simultaneous calculation of blood flow velocity, shear stress and drug distribution. Our calculations show that drug uptake by the arterial tissue is dependent both on the patterns of flow disruption near the wall, as well as on the relative positioning of drug-eluting struts. Overlapping stent struts lead to localized peaks of drug concentration that may increase the risk of thrombosis. Such peaks could be avoided by anisotropic stent structure or asymmetric drug release designed to yield homogeneous drug distribution along the coronary artery and, at the least, suggest that these issues need to remain in the forefront of consideration in clinical practice.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant R01 GM 49039)en_US
dc.publisherElsevieren_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/J.JCONREL.2016.07.023en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourcePMCen_US
dc.titleDrug deposition in coronary arteries with overlapping drug-eluting stentsen_US
dc.typeArticleen_US
dc.identifier.citationRikhtegar, Farhad et al. “Drug Deposition in Coronary Arteries with Overlapping Drug-Eluting Stents.” Journal of Controlled Release 238 (September 2016): 1–9 © 2016 Elsevier B.V.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Institute for Medical Engineering & Scienceen_US
dc.contributor.mitauthorRikhtegar Nezami, Farhad
dc.contributor.mitauthorEdelman, Elazer R
dc.relation.journalJournal of Controlled Releaseen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2017-12-14T18:59:23Z
dspace.orderedauthorsRikhtegar, Farhad; Edelman, Elazer R.; Olgac, Ufuk; Poulikakos, Dimos; Kurtcuoglu, Vartanen_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-4210-3177
dc.identifier.orcidhttps://orcid.org/0000-0002-7832-7156
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record